Evidence map›Paper›PMID 42136096›Full record

ArticleStatistics in medicine2026

Longitudinal Sparse Single-Omics Factor Analysis for High-Dimensional Blood Biomarkers in Alzheimer's Disease.

Haotian Zou, Rima Kaddurah-Daouk, Sheng Luo, Alzheimer's Disease Neuroimaging Initiative

Abstract read
In one paragraph

Article in Statistics in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Haotian ZouDepartment of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0002-3595-8716
Rima Kaddurah-DaoukDepartment of Psychiatry and Behavioral Sciences, Duke University, Durham, North Carolina, USA.
Sheng LuoDepartment of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0003-4214-5809
Alzheimer's Disease Neuroimaging Initiative

Funding

Project 4 - Mechanistic studies on the role of the gut microbiome in models for Alzheimer's diseaseU19AG063744 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Rima F Kaddurah-Daouk · 2019 to 2026
$54.1M
Research Education Component CoreP30AG072958 · NIA · DUKE UNIVERSITY · PI Heather E. Whitson · 2021 to 2026
$24.1M
Metabolomic Signatures for Disease Sub-classification and Target Prioritization in AMP-ADU01AG061359 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KASTENMULLER, GABI · 2018 to 2022
$10.0M
The Role of Chemical Exposures in Alzheimer's Disease (AD) and its TrajectoryU01AG088562 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Oliver Fiehn, LEE E. GOLDSTEIN · 2024 to 2026
$7.2M
Metabolic Signatures Underlying Vascular Risk Factors for Alzheimer-type DementiasRF1AG051550 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KLING, MITCHEL ALLAN · 2015 to 2016
$6.3M
Metabolic Networks and Pathways Predictive of Sex Differences in AD Risk and Responsiveness to TreatmentRF1AG059093 · NIA · DUKE UNIVERSITY · PI BRINTON, ROBERTA EILEEN, CHANG, RUI · 2018 to 2018
$5.9M
Metabolic Networks and Pathways in Alzheimer's DiseaseR01AG046171 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F · 2014 to 2017
$4.4M
Metabolic Network Analysis of Biochemical Trajectories in Alzheimer's DiseaseRF1AG057452 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KASTENMULLER, GABI · 2017 to 2017
$3.5M
Gut Liver Brain Biochemical Axis in Alzheimer's DiseaseRF1AG058942 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, VAN DUIJN, CORNELIA MARJA · 2018 to 2018
$3.4M
Metabolomic Signatures Predictive of Outcomes to Treatments for Major DepressionR01MH108348 · NIMH · DUKE UNIVERSITY · PI DUNLOP, BOADIE W, KADDURAH-DAOUK, RIMA F · 2016 to 2019
$2.7M
Metabolic age to define influences of the lipidome on brain aging in Alzheimer's diseaseR01AG081322 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Matthias Arnold, Rima F Kaddurah-Daouk · 2023 to 2026
$2.6M
Integrative modeling and dynamic prediction of Alzheimer's diseaseR01AG064803 · NIA · DUKE UNIVERSITY · PI LUO, SHENG · 2020 to 2024
$2.3M
NIA NIH HHS P30 AG072958NIA NIH HHS P30AG072958NIA NIH HHS R01 AG046171NIA NIH HHS R01 AG064803NIA NIH HHS R01AG064803NIA NIH HHS R01 AG081322NIA NIH HHS RF1 AG051550NIA NIH HHS RF1 AG057452NIA NIH HHS RF1 AG058942NIA NIH HHS RF1 AG059093NIA NIH HHS U01 AG061359NIA NIH HHS U01 AG088562NIA NIH HHS U19 AG063744NIMH NIH HHS R01 MH108348
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder whose molecular mechanisms involve multiple biological pathways. Longitudinal blood-based omics data, such as lipidomics and metabolomics profiles, offer promising noninvasive biomarkers for early detection and prognosis, yet they are high-dimensional, sparse, and exhibit complex temporal and cross-feature correlations. The primary goal of this study is to identify which omics data types are most strongly associated with time to dementia onset in patients with mild cognitive impairment (MCI) at baseline. To address this, we propose a longitudinal sparse single-omics factor analysis (LS-SOFA) framework that models each omics view through view-specific latent factors and feature-weight matrices, with temporal dynamics captured by functional principal component analysis (FPCA). The resulting functional principal component (FPC) scores are incorporated into a survival model to test whether each omics view is associated with time to dementia onset. An efficient covariance-based estimation algorithm substantially reduces computational and memory cost, enabling large-scale application in the Alzheimer's Disease Neuroimaging Initiative (ADNI) study. In simulations, LS-SOFA achieves higher longitudinal estimation accuracy and more stable hypothesis testing than competing methods. Applied to five blood-based omics views from ADNI, LS-SOFA identified plasma lipidomics and serum metabolomics from FIA and UPLC as significantly associated with dementia risk after FDR adjustment, with nominal evidence of association for gut microbial metabolomics from serum. The top features within each omics view reveal biologically interpretable metabolic pathways that may serve as blood-based biomarkers for AD progression.

Indexed as

Alzheimer DiseaseBiomarkersAlgorithmsCognitive DysfunctionComputer SimulationDisease ProgressionFactor Analysis, StatisticalFemaleHumansLipidomicsLongitudinal StudiesMetabolomicsPrincipal Component AnalysisBiomarkersADNIbiomarker discoverycovariance modelingfunctional principal component analysishigh‐dimensional datasurvival association

Identifiers

PMID42136096
PMCPMC13222108

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.